Skip to main content
. 2021 Oct 13;134(22):2666–2674. doi: 10.1097/CM9.0000000000001781

Table 2.

Characteristics of included trials on comparison between intravenous thrombolysis and control group.

Intervention methods Time windows
Studies Included clinical criteria IG CG IG CG
Michel et al 2012[14] Patients with unknown stroke onset, age 18 to 80 years, NIHSS 6 to 22 at the start of treatment, hemispheric stroke syndrome, Pre-stroke mRS = 0 to 1 and Barthel index≥95, CT-to-treatment interval (<60 min), et al IVT with alteplase 0.9mg/kg placebo 564.0 min (9.4 h) 437.5 min (7.3 h)
Thomalla et al 2018[16] Patients with clinical signs of acute stroke, ages 18 to 80 years, and had been able to carry out usual activities. Patients either recognized stroke symptoms on awakening or could not report the timing of the onset of symptoms (e.g., as a result of aphasia or confusion). Patient was last known to be well had to be more than 4.5 h, et al IVT with alteplase 0.9 mg per kilogram of body weight (with 10% administered as a bolus and the remainder by infusion during a 60 min placebo 10.3 h 10.4 h
Ma et al 2019[17] Patients were at least 18 years; had excellent functional status before enrollment (defined by a score of <2 on the mRS 0 to 6, had a stroke with a clinical severity score at presentation of 4 to 26 on the NIHSS, on which scores range from 0 to 42, with higher scores indicating greater deficit, et al IVT with alteplase 0.9 mg per kilogram of body weight [maximum, 90 mg], administered as a 10% bolus and 90% infusion over 1 h placebo 432.0 min (7.2 h) 450.0 min (7.5 h)
Ringleb et al 2019[18] Patients with AIS could be included if treatment could be started within 4.5 to 9 h after symptom onset. Patients who woke up with stroke symptoms could be included if the mean between time last seen well and symptom recognition was between these limits IVT alteplase 0.9 mg/kg (maximum 90 mg), given as 10% of total dose bolus over 1 min, then the remaining 90% as an infusion over 60 min. placebo 7.7 h 7.3 h

IG: intravenous thrombolysis group; CG: Control group; mRS: modified Rankin scale; NIHSS: National Institutes of Health Stroke Scale; CT: computed tomography.